Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 9,955

Document Document Title
WO/2019/137430A1
The present invention provides an organic compound of a specific structure. The organic compound is characterized by being represented by the following general formula (1): In the formula (1), X1-X8 are respectively and independently sel...  
WO/2019/138227A1
Compounds that are useful as inhibitors of the activity of Wee-1 kinase are provided. Also provided are pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods...  
WO/2019/136159A1
Provided herein are compositions and methods useful for the expansion of hematopoietic stem and progenitor cells. In accordance with the composition and methods described herein, hematopoietic stem and progenitor cells may be expanded, f...  
WO/2019/134985A1
The invention provides new heterocyclic compounds having the general formula (le), wherein R1, R1a and R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the co...  
WO/2019/129681A1
The present invention provides novel compounds having the general formula: wherein R1, R2, X, Y and A are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2019/121458A1
The present invention relates to heterocyclic compounds, particularly for use in electronic devices. The invention further relates to a method for producing the compounds according to the invention and to electronic devices comprising th...  
WO/2019/126733A1
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I): wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, a...  
WO/2019/121406A1
The invention relates to compounds of formula I inhibiting Rho Kinase that are tyrosine analogues derivatives, processes of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly t...  
WO/2019/119145A1
The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs...  
WO/2019/126686A1
The present disclosure relates to l,2-dihydro-3H-pyrazol-3-one compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells (e.g. cochlear cells), including inducing the stem/progenitor cells to prolifer...  
WO/2019/126083A1
Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, X, Y, Z, R1, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or ...  
WO/2019/125977A1
Disclosed are compounds of Formula (I): N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, a...  
WO/2019/122129A1
The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds...  
WO/2019/121885A1
The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.  
WO/2019/121840A1
The present invention provides compounds of formula (I) that are PDEl enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also p...  
WO/2019/126730A1
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula (I); where A1, A2, G, R1, R2, R3, R4, and W are d...  
WO/2019/121596A1
The present invention relates to triazolo pyridines of formula (II) and their use as modulators of -secretase. In particular, the present invention relates to compounds which interfere with -secretase and/or its substrate and there...  
WO/2019/126113A1
Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, an...  
WO/2019/116651A1
This nitrogen-containing heterocyclic compound production method is characterized in that in a sublimation purification apparatus (101) provided with at least a temperature-controlled boat section (11), a collection section (13), and a t...  
WO/2019/114769A1
Disclosed are a compound containing pyridoindole and the use thereof in an organic electroluminescence device. The compound is composed of pyridoindole groups, and has a deep HOMO energy level and hole mobility and is suitable as a hole ...  
WO/2019/118909A1
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.  
WO/2019/114611A1
Disclosed in the present invention are an aromatic amine compound and an application of same in an organic electronic device, and in particular, in an organic electroluminescent diode. Also disclosed in the present invention are an organ...  
WO/2019/111218A1
The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatmen...  
WO/2019/106004A1
The invention concerns compounds having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising t...  
WO/2019/043451A8
A compound characterized by comprising at least one of each of a first divalent organic group represented by formula (1), and a second divalent organic group selected from formula (2a) and formula (2b), wherein the first divalent organic...  
WO/2019/106197A1
The invention relates to new compounds of formula (I): wherein X represents a halogen atom selected from the group consisting of fluorine, chlorine, bromine and iodine, which are useful for the preparation of 4,4'dihalobenzophenones of f...  
WO/2019/101183A1
Pyrazolopyridinone compounds, the pharmaceutical compositions comprising said compounds, and the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and their use in the treatment of diseases, e.g. cancer.  
WO/2019/103070A1
Provided are: a compound that is useful for the prevention of and/or as a treatment agent for a disease in which a group II mGlu receptor is involved; and a medical application of said compound. Provided is a compound represented by form...  
WO/2019/102494A1
The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabo...  
WO/2019/101182A1
Pyrazolopyridinone compounds, the pharmaceutical compositions comprising said compounds, and the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and their use in the treatment of diseases, e.g. cancer.  
WO/2019/104285A1
Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, inclu...  
WO/2019/102490A1
The present invention relates to novel intermediates of Eribulin and process for the preparation of the same. The process of the present invention is commercially viable and can be easily adopted for plant scale operations. The present i...  
WO/2019/101047A1
Disclosed are a bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders, a method for treating and/or preventing hepatitis virus-related diseases or disorders by using the bisdiazabicyclo com...  
WO/2019/095920A1
The present invention relates to an organic compound represented by formula (1), and applications thereof in organic electroluminescence components. The compound in the present invention has a high glass transition temperature and high m...  
WO/2019/097544A1
The invention provides a compound for specific detection of SLNPV. Further, the invention provides a probe for specific detection of SLNPV. The probe comprises of a substrate embedded with the compound. The invention also provides a kit ...  
WO/2019/093284A1
The present invention addresses the problem of providing a novel compound that exhibits CGRP-receptor antagonism and is useful for treatment of a variety of diseases involving CGRP receptors. The present invention pertains to a condensed...  
WO/2019/091400A1
Provided are a salt form and crystal form of a pyridopyrimidine compound and a preparation method thereof. In particular, the present invention provides a free base and sulfate of a compound of formula (I), a crystal form thereof, and a ...  
WO/2019/085759A1
The invention relates to a compound provided with an aza-spirofluorene and aryl ketone core, a preparation method thereof, and an application of the same in organic light-emitting diodes (OLEDs). The compound comprises aza-spirofluorene ...  
WO/2019/086712A1
The present invention relates to a compound having the following formula (I): (I) wherein: - R is a (C1-C6)alkyl group;- R'' is preferably H;- Ar is a (C5-C12)arylene radical;- X1 is -C(=O)- or -SO2-; and- R' is chosen from the group con...  
WO/2019/085996A1
Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 double-kinase activity inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV)...  
WO/2019/086141A1
The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV rep...  
WO/2019/088159A1
The present application provides a substituted purine compound represented by formula (1) and a pharmaceutically acceptable salt thereof, which exhibit a TLR7-inhibiting effect and are useful for therapy, etc., of autoimmune diseases. [I...  
WO/2019/090229A1
Organic photovoltaic cells (OPVs) and their compositions are described herein. In one or more embodiments, the acceptor with an active layer of an OPV includes is a non-fullerene acceptor. Such non-fullerene acceptors may provide improve...  
WO/2019/086142A1
The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV rep...  
WO/2019/081353A1
The application relates to novel substituted imidazopyridine amides of formula (I), to methods for the production thereof, to the use thereof alone or in combination for the treatment and/or prophylaxis of disorders, and to the use there...  
WO/2019/076986A1
The present invention relates to a compound of formula (II), as well as to a process for preparing the compounds of formula (II) by a chemoselective Sonogashira reaction. It also relates to a pharmaceutical composition comprising at leas...  
WO/2019/078040A1
Provided is a tetrazolopyridine compound which is capable of maintaining the LUMO level low when the tetrazolopyridine compound is used as an organic semiconductor material. A compound represented by formula (1), or a bonded body of the ...  
WO/2019/076336A1
The present invention relates to a pyrazolyl-containing tricyclic derivative, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as shown in the general formula (I), a preparatio...  
WO/2019/072235A1
The present invention relates to a series of 2,6-dioxaspiro [4,5] decane derivatives and applications thereof in preparation of opiate receptor μ agonist related drugs; and in particular relates to the derivative compounds shown in form...  
WO/2019/075092A1
In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.  

Matches 1 - 50 out of 9,955